Yuya Oguro

This inventor holds 21 USPTO granted patents and 5 published patent applications, plus 3 CIPO patents and 12 EPO patents, primarily in Heterocyclic Compounds. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yuya Oguro. Retrieved from https://idiyas.com/inventor/yuya-oguro

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 5)

% Patents Active = 95.2

CIPO Patents = 3 (Patent Applications = 5)

EPO Patents = 12 (Patent Applications = 17)

Average Co-Inventor Count = 4.5

ph-index = 4

Forward Citations = 61(Granted Patents)

Location History:

Tsukuba, JP (2012 - 2013)
Kanagawa, JP (2014 - 2023)
Fujisawa, JP (2018 - 2024)

Company Filing History:

21 out of 1,226

Takeda Pharmaceutical Company Limited

patents

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

NMDA Antagonists

GPR139 Antagonists

Thienopyrimidine

Fused Heterocycle

Crystalline Forms

Bipyridin Derivatives

CDC7 Kinase Inhibitors

Depression Treatment

Pharmaceuticals

Chemical Derivatives

Antagonist Compounds

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12637418 - Heterocyclic compounds as antagonist of NMDA (2026-05-26),

2. 12630509 - Heterocyclic NMDA antagonists (2026-05-19),

3. 12590086 - 3-((1H-pyrazol-4-yl)methyl)-6'-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression (2026-03-31),

4. 11952344 - Heterocyclic compound and use thereof (2024-04-09),

5. 11834409 - Heterocyclic NMDA antagonists (2023-12-05),

6. 11827601 - Heterocyclic NMDA antagonists (2023-11-28),

7. 11746109 - Crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate (2023-09-05),

8. 11713311 - Heterocyclic compound (2023-08-01),

9. 11702419 - Heterocyclic compound and use thereof (2023-07-18),

10. 11230541 - Heterocyclic compound (2022-01-25),

11. 10807987 - Heterocyclic compound and use thereof (2020-10-20),

12. 10610520 - Heterocyclic compound (2020-04-07),

13. 10323026 - Heterocyclic compound (2019-06-18),

14. 10131653 - Heterocyclic compound (2018-11-20),

15. 9655900 - Heterocyclic compound (2017-05-23),

Title: The Innovative Mind of Yuya Oguro: Pioneering Heterocyclic Compounds in Pharmaceuticals

Introduction:

Yuya Oguro, an esteemed inventor based in Kanagawa, Japan, has made significant contributions to the field of pharmaceuticals with his groundbreaking research and inventive spirit. With a total of 18 patents to his name, Oguro's work has focused on developing novel compounds for the treatment of various neurological disorders and conditions.

Latest Patents:

Oguro's latest patents showcase his expertise in the creation of heterocyclic compounds with potential therapeutic applications. One of his recent patents is for a heterocyclic compound designed to have an antagonistic action on the NMDA receptor, specifically targeting the NR2B subunit. This compound shows promise as a prophylactic or therapeutic agent for conditions such as depression, bipolar disorder, migraine, pain, and symptoms peripheral to dementia. Another patent highlights a compound with similar properties, emphasizing its potential for treating a range of neurological ailments.

Career Highlights:

Yuya Oguro is a key innovator at Takeda Pharmaceutical Company Limited, a leading pharmaceutical company known for its cutting-edge research and development efforts. Through his work at Takeda, Oguro has been instrumental in driving forward advancements in the field of neuropharmacology, with a focus on improving treatment options for patients with neurological disorders.

Collaborations:

In his collaborative endeavors, Oguro has worked closely with esteemed colleagues such as Taku Kamei and Makoto Kamata. Together, they have pooled their expertise to explore new avenues in pharmaceutical research, pushing the boundaries of innovation and discovery.

Conclusion:

Yuya Oguro's pioneering work in developing heterocyclic compounds underscores his commitment to advancing pharmaceutical science and improving patient care. His dedication to innovation and his collaborative efforts have not only led to a series of impactful patents but also positioned him as a respected figure in the field. As Oguro continues to push the boundaries of pharmaceutical research, his contributions are sure to shape the future of neuropharmacology and beyond.

Profile summary based on public USPTO records.